Skip to content

Effect of Nano-crystalline Hydroxyapatite (SybografTM) Vs Beta Tri-Calcium Phosphate (Sybograf-TTM) in the Treatment of Intrabony Defects in Chronic Periodontitis Patients.

Comparative Clinical and Radiographic Evaluation of the Effect of Nano-crystalline Hydroxyapatite (SybografTM) Vs Beta Tri-Calcium Phosphate (Sybograf-TTM) in the Treatment of Intrabony Defects in Chronic Periodontitis Patients.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/01/011375
Enrollment
40
Registered
2018-01-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic Periodontitis patients with interproximal bone defects of 5 mm or more.

Interventions

Intervention1: Nano-crystalline Hydroxyapatite (SybografTM): Commercially available Nano-crystalline Hydroxyapatite (SybografTM) Control Intervention1: Beta Tri-Calcium Phosphate (Sybograf-TTM): Comme

Sponsors

Abhishek singh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age group between 20-60years 2. Diagnosis with chronic periodontitis 3. Patients in good systemic health with no contraindication to periodontal surgery 4. Patients having infrabony defects with pocket depths of 5mm or more and with radiographic evidence of vertical or angular bone loss in the affected sites. 5. Involved teeth to be vital and asymptomatic 6. Systemically healthy individuals with no underlying medical conditions.

Exclusion criteria

Exclusion criteria: 1. One â?? wall osseous defects. 2. Patients suffering from any systemic diseases or with compromised immune system. 3. Patients who had received any type of periodontal therapy for the past 6 months 4. Patients taking any immuno-suppressive drugs like corticosteroids 5. Patients with a known history of allergy to doxycycline or Chlorhexidine or any other medicine be used in the study. 6. Patients showing unacceptable oral hygiene compliance during / after the phase I therapy. 7. Patients taking any drug known to cause gingival enlargement. 8. Pregnant and/or lactating mothers. 9. Patients who were smokers or had tobacco in any other form. 10. Endodontically treated teeth. 11. Patient on anticoagulant therapy 12. Patient with bleeding disorders.

Design outcomes

Secondary

MeasureTime frame
Radiographic bone fill will be evaluated using intraoral periapical radiographs of the surgical site.Timepoint: Radiographs will be taken at baseline, immediately after surgery and at sixth month after surgery.

Primary

MeasureTime frame
1. Plaque Index (P.I.) (Turskey-Gilmore-Glickman Modification Of Quigley Hein). 2. Gingival Index (G.I.) (Loe & Silness, 1963). 3. Probing Pocket Depth (PPD). 4. Clinical Attachment Level (CAL).Timepoint: The clinical parameters are recorded at baseline, 1 month, 3 months, and 6 months after surgery.

Countries

India

Contacts

Public ContactAbhishek singh

Nair hospital dental college

maladixit25@gmail.com9870611172

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026